Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II

Journal of Medicinal Chemistry

Volumn 50, Issue 14, 2007, Pages 3267-3273

  Bařinka, Cyril ^a   Rovenská, Miroslava ^b,c   Mlčochová, Petra ^b,c   Hlouchová, Klára ^b,c   Plechanovová, Anna ^b,c   Majer, Pavel ^d   Tsukamoto, Takashi ^d   Slusher, Barbara S ^d   Konvalinka, Jan ^b,c   Lubkowski, Jacek ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d MGI Pharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (PHOSPHONOMETHYL)PENTANEDIOIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ENZYME INHIBITOR; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMIC ACID DERIVATIVE; N ACETYLASPARTYLGLUTAMIC ACID; PHOSPHOSERINE; QUISQUALIC ACID; RECOMBINANT ENZYME; SERINE DERIVATIVE; SERINE SULFATE; UNCLASSIFIED DRUG; WILLARDIINE;

ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; ENZYME INHIBITION; HUMAN; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PHARMACOPHORE; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MODELS, MOLECULAR; MOLECULAR MIMICRY; PROTEIN CONFORMATION; RECOMBINANT PROTEINS;

EID: 34447521874     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070133w     Document Type: Article

References (45)

1. Doble, A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol. Ther. 1999, 81, 163-221.
2. Sacha, P.; Zámecnik, J.; Barinka, C.; Hlouchova, K.; Vicha, A.; Mlcochova, P.; Hilgert, I.; Eckschlager, T.; Konvalinka, J. Expression of glutamate carboxypeptidase II in human brain. Neuroscience 2007, 144, 1361-1372.
3. Troyer, J. K.; Beckett, M. L.; Wright, G. L., Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer 1995, 62, 552-558.
4. Neale, J. H.; Olszewski, R. T.; Gehl, L. M.; Wroblewska, B.; Bzdega, T. The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol. Sci. 2005, 26, 477-484.
5. Carpenter, K. J.; Sen, S.; Matthews, E. A.; Flatters, S. L.; Wozniak, K. M.; Slusher, B. S.; Dickenson, A. H. Effects of GCP-II inhibition on responses of dorsal horn neurones after inflammation and neuropathy: an electrophysiological study in the rat. Neuropeptides 2003, 37, 298-306.
6. Ghadge, G. D.; Slusher, B. S.; Bodner, A.; Canto, M. D.; Wozniak, K.; Thomas, A. G.; Rojas, C.; Tsukamoto, T.; Majer, P.; Miller, R. J.; Monti, A. L.; Roos, R. P. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc. Natl. Acad. Sci. U.S.A 2003, 100, 9554-9559.
7. Slusher, B. S.; Vornov, J. J.; Thomas, A. G.; Hurn, P. D.; Harukuni, I.; Bhardwaj, A.; Traystman, R. J.; Robinson, M. B.; Britton, P.; Lu, X. C.; Tortella, F. C.; Wozniak, K. M.; Yudkoff, M.; Potter, B. M.; Jackson, P. F. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med. 1999, 5, 1396-1402.
8. Olszewski, R. T.; Bukhari, N.; Zhou, J.; Kozikowski, A. P.; Wroblewski, J. T.; Shamimi-Noori, S.; Wroblewska, B.; Bzdega, T.; Vicini, S.; Barton, F. B.; Neale, J. H. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J. Neurochem. 2004, 89, 876-885.
9. Wroblewska, B.; Wroblewski, J. T.; Pshenichkin, S.; Surin, A.; Sullivan, S. E.; Neale, J. H. N-Acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J. Neurochem. 1997, 69, 174-181.
10. Thomas, A. G.; Liu, W.; Olkowski, J. L.; Tang, Z.; Lin, Q.; Lu, X. C.; Slusher, B. S. Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF-beta. Eur. J. Pharmacol. 2001, 430, 33-40.
11. Bruno, V.; Wroblewska, B.; Wroblewski, J. T.; Fiore, L.; Nicoletti, F. Neuroprotective activity of N-acetylaspartylglutamate in cultured cortical cells. Neuroscience 1998, 85, 751-757.
12. Barinka, C.; Rinnova, M.; Sacha, P.; Rojas, C.; Majer, P.; Slusher, B. S.; Konvalinka, J. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J. Neurochem. 2002, 80, 477-487.
13. Serval, V.; Galli, T.; Cheramy, A.; Glowinski, J.; Lavielle, S. In vitro and in vivo inhibition of N-acetyl-L-aspartyl-L- glutamate catabolism by N-acylated L-glutamate analogs. J. Pharmacol. Exp. Ther. 1992, 260, 1093-1100.
14. Subasinghe, N.; Schulte, M.; Chan, M. Y.; Roon, R. J.; Koerner, J. F.; Johnson, R. L. Synthesis of acyclic and dehydroaspartic acid analogues of Ac-Asp-Glu-OH and their inhibition of rat brain N-acetylated alpha-linked acidic dipeptidase (NAALA dipeptidase). J. Med. Chem. 1990, 33, 2734-2744.
15. Jackson, P. F.; Cole, D. C.; Slusher, B. S.; Stetz, S. L.; Ross, L. E.; Donzanti, B. A.; Trainor, D. A. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J. Med. Chem. 1996, 39, 619-622.
16. Kozikowski, A. P.; Nan, F.; Conti, P.; Zhang, J.; Ramadan, E.; Bzdega, T.; Wroblewska, B.; Neale, J. H.; Pshenichkin, S.; Wroblewski, J. T. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J. Med. Chem. 2001, 44, 298-301.
17. Wone, D. W.; Rowley, J. A.; Garofalo, A. W.; Berkman, C. E. Optimizing phenylethylphosphonamidates for the inhibition of prostate-specific membrane antigen. Bioorg. Med. Chem. 2006, 14, 67-76.
18. Jackson, P. F.; Tays, K. L.; Maclin, K. M.; Ko, Y. S.; Li, W.; Vitharana, D.; Tsukamoto, T.; Stoermer, D.; Lu, X. C.; Wozniak, K.; Slusher, B. S. Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. J. Med. Chem. 2001, 44, 4170-4175.
19. Majer, P.; Jackson, P. F.; Delahanty, G.; Grella, B. S.; Ko, Y. S.; Li, W.; Liu, Q.; Maclin, K. M.; Polakova, J.; Shaffer, K. A.; Stoermer, D.; Vitharana, D.; Wang, E. Y.; Zakrzewski, A.; Rojas, C.; Slusher, B. S.; Wozniak, K. M.; Burak, E.; Limsakun, T.; Tsukamoto, T. Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J. Med. Chem. 2003, 46, 1989-1996.
20. Stoermer, D.; Liu, Q.; Hall, M. R.; Flanary, J. M.; Thomas, A. G.; Rojas, C.; Slusher, B. S.; Tsukamoto, T. Synthesis and biological evaluation of hydroxamate-based inhibitors of glutamate carboxypeptidase II. Bioorg. Med. Chem. Lett. 2003, 13, 2097-2100.
21. Ding, P.; Miller, M. J.; Chen, Y.; Helquist, P.; Oliver, A. J.; Wiest, O. Syntheses of conformationally constricted molecules as potential NAALADase/PSMA inhibitors. Org. Lett. 2004, 6, 1805-1808.
22. Majer, P.; Hin, B.; Stoermer, D.; Adams, J.; Xu, W.; Duvall, B. R.; Delahanty, G.; Liu, Q.; Stathis, M. J.; Wozniak, K. M.; Slusher, B. S.; Tsukamoto, T. Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1′ side chain. J. Med. Chem. 2006, 49, 2876-2885.
23. Davis, M. I.; Bennett, M. J.; Thomas, L. M.; Bjorkman, P. J. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc. Natl. Acad. Sci. U.S.A 2005, 102, 5981-5986.
24. Mesters, J. R.; Barinka, C.; Li, W.; Tsukamoto, T.; Majer, P.; Slusher, B. S.; Konvalinka, J.; Hilgenfeld, R. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J. 2006, 25, 1375-1384.
25. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. In Methods in Enzymology; Carter Jr., C. W., Sweet, R. M., Eds.; Academic Press: New York 1997; Vol. 276, pp 307-326.
26. Barinka, C.; Starkova, J.; Konvalinka, J.; Lubkowski, J. A high-resolution structure of ligand-free glutamate carboxypeptidase II. Acta Crystallogr. F 2007, 63, 150-153.
27. Murshudov, G. N.; Vagin, A. A.; Lebedev, A.; Wilson, K. S.; Dodson, E. J. Efficient anisotropic refinement of macromolecular structures using FFT. Acta Crystallogr. D 1999, 55, 247-255.
28. McRee, D. E. XtalView/Xfit. A versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 1999, 125, 156-165.
29. Laskowski, R. A.; McArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a program to check thestereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.
30. Collaborative Computational Project, Number 4. "The CCP4 Suite: Programs for Protein Crystallography". Acta Crystallogr. D 1994, 50, 760-763.
31. Serval, V.; Barbeito, L.; Pittaluga, A.; Cheramy, A.; Lavielle, S.; Glowinski, J. Competitive inhibition of N-acetylated-alpha-linked acidic dipeptidase activity by N-acetyl-L-aspartyl-beta-linked L-glutamate. J. Neurochem. 1990, 55, 39-46.
32. Robinson, M. B.; Blakely, R. D.; Coyle, J. T. Quisqualate selectively inhibits a brain peptidase which cleaves N-acetyl-L-aspartyl- L-glutamate in vitro. Eur. J. Pharmacol. 1986, 130, 345-347.
33. Vitharana, D.; France, J. E.; Scarpetti, D.; Bonneville, G. W.; Majer, P.; Tsukamoto, T. Synthesis and biological evaluation of (R)- and (S)-2-(phosphonomethyl)pentanedioic acids as inhibitors of glutamate carboxypeptidase II. Tetrahedron: Asymmetry 2002, 13, 1609-1614.
34. Flippen, J. L.; Gilardi, R. D. Quisqualic acid. Acta Crystallogr. B 1976, 32, 951-953.
35. Boden, P.; Bycroft, B. W.; Chhabra, S. R.; Chiplin, J.; Crowley, P. J.; Grout, R. J.; King, T. J.; McDonald, E.; Rafferty, P.; Usherwood, P. N. The action of natural and synthetic isomers of quisqualic acid at a well-defined glutamatergic synapse. Brain Res. 1986, 385, 205-211.
36. Jackson, D. E.; Bycroft, B. W.; King, T. J. Crystallographic studies and semi-empirical MNDO calculations on quisqualic acid and its analogs. Systems containing unusual pyramidal heterocyclic ring nitrogens. J. Comput.-Aided Mol. Des. 1989, 2, 321-328.
37. Tiffany, C. W.; Cai, N. S.; Rojas, C.; Slusher, B. S. Binding of the glutamate carboxypeptidase II (NAALADase) inhibitor 2-PMPA to rat brain membranes. Eur. J. Pharmacol. 2001, 427, 91-96.
38. Robinson, M. B.; Blakely, R. D.; Couto, R.; Coyle, J. T. Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J. Biol. Chem. 1987, 262, 14498-14506.
39. Matzen, L.; Engesgaard, A.; Ebert, B.; Didriksen, M.; Frolund, B.; Krogsgaard-Larsen, P.; Jaroszewski, J. W. AMPA receptor agonists: synthesis, protolytic properties, and pharmacology of 3-isothiazolol bioisosteres of glutamic acid. J. Med. Chem. 1997, 40, 520-527.
40. Hill, R. A.; Wallace, L. J.; Miller, D. D.; Weinstein, D. M.; Shams, G.; Tai, H.; Layer, R. T.; Willins, D.; Uretsky, N. J.; Danthi, S. N. Structure-activity studies for alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropanoic acid receptors: acidic hydroxyphenylalanines. J. Med. Chem. 1997, 40, 3182-3191.
41. Kraulis, P. E. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. App. Crystallogr. 1991, 24, 946-950.
42. Esnouf, R. M. Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. Acta Crystallogr. D 1999, 55, 938-940.
43. Merritt, E. A.; Murphy, M. E. Raster3D version 2.0. A program for photorealistic molecular graphics. Acta Crystallogr. D 1994, 50, 869-873.
44. DeLano, W. L. The PyMOL Molecular Graphics System; Delano Scientific: Palo Alto, CA, 2002.
45. Mesters, J.R.; Henning, K.; Hilgenfeld, R. Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. Acta Crystallogr. D 2007, 63, 508-513.